GMM Pfaudler Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript GMM Pfaudler Ltd filed with BSE on 13 Aug 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
GMM Pfaudler reported consolidated Q1 FY27 revenue of INR 925 crores, up 16% year-on-year, with EBITDA of INR 94 crores, down 7% year-on-year but up 25% quarter-on-quarter, and profit after tax of INR 22 crores, more than double the prior year. The company reorganized itself from a geographic structure into four global technology divisions - CRT, PPT, HET, and PST - and reported a record order backlog of INR 2,289 crores, up approximately 20% year-on-year. Management also discussed debt reduction plans, tax rate normalization, and margin improvement initiatives across the newly formed divisions.
Numbers mentioned
Order backlog: INR 2,289 crores (Q1 FY27)
p. 6
“We closed the quarter with a record order backlog of INR 2,289 crores representing an increase of approximately 20% year on year, supported by a healthy order intake of over INR 1,007 crores during the quarter.”
Gregory Gelhaus, page 6 of the filed PDF · View the filing
Order intake: INR 1,007 crores (Q1 FY27)
p. 8
“During the quarter, the company recorded a total order intake of INR 1,007 crores, which is flat year-on-year.”
Alexander Poempner, page 8 of the filed PDF · View the filing
Consolidated revenue: INR 925 crores (Q1 FY27)
p. 8
“Consolidated revenue for the quarter stood at INR 925 crores, registering a growth of 16% on a year-on-year basis.”
Alexander Poempner, page 8 of the filed PDF · View the filing
EBITDA: INR 94 crores (Q1 FY27)
p. 8
“EBITDA for the quarter stood at INR 94 crores.”
Alexander Poempner, page 8 of the filed PDF · View the filing
Profit after tax: INR 22 crores (Q1 FY27)
p. 8
“Profit after tax for the quarter stood at INR 22 crores, which more than doubled year-on-year.”
Alexander Poempner, page 8 of the filed PDF · View the filing
CRT division revenue: INR 466 crores (Q1 FY27)
p. 6
“Our CRT division reported revenues of INR 466 crores representing a growth of 10% year-on-year.”
Gregory Gelhaus, page 6 of the filed PDF · View the filing
CRT order intake: INR 502 crores (Q1 FY27)
p. 6
“Order intake during the quarter stood at INR 502 crores, representing a growth of 23% year-on-year.”
Gregory Gelhaus, page 6 of the filed PDF · View the filing
PPT division revenue: INR 255 crores (Q1 FY27)
p. 7
“The division reported revenue of INR 255 crores growing 23% year-on-year.”
Gregory Gelhaus, page 7 of the filed PDF · View the filing
PPT order intake: INR 367 crores (Q1 FY27)
p. 7
“Order intake stood at INR 367 crores, growing 64% year-on-year.”
Gregory Gelhaus, page 7 of the filed PDF · View the filing
HET division revenue: INR 74 crores (Q1 FY27)
p. 7
“The HET division reported revenue of INR 74 crores which is flat year-on-year.”
Gregory Gelhaus, page 7 of the filed PDF · View the filing
HET order intake growth: more than 700% year-on-year (Q1 FY27)
p. 7
“Order intake during the quarter stood at INR 58 crores which is increasing more than 700% year-on-year.”
Gregory Gelhaus, page 7 of the filed PDF · View the filing
PST division revenue: INR 131 crores (Q1 FY27)
p. 7
“Our PST division reported revenue of INR 131 crores registering a growth of 46% year-on-year.”
Gregory Gelhaus, page 7 of the filed PDF · View the filing
PST order intake: INR 80 crores (Q1 FY27)
p. 7
“Order intake during the quarter stood at INR 80 crores, whereas the order intake for Q1 FY26 was INR 363 crores, which was represented by one large defence order.”
Gregory Gelhaus, page 7 of the filed PDF · View the filing
Interest cost: 6% to 7% (FY27)
p. 27
“So, for your modeling, I would assume 6% to 7%.”
Alexander Poempner, page 27 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Debt repayment — approximately EUR 7 million · by end of Q2 FY27
stated firmly by Alexander Poempner
p. 10
“we intend to repay some debt at the group level and will repay an amount of approximately EUR 7 million of debt by the end of Q2 in this financial year.”
Alexander Poempner, page 10 of the filed PDF · View the filing
EBITDA margin — 15%
stated as an aspiration by Tarak Patel
p. 16
“as a company, we obviously have always said like a 15% EBITDA margin for the company is something that we aspire towards.”
Tarak Patel, page 16 of the filed PDF · View the filing
EBITDA margin — 15% minimum
stated firmly by Alexander Poempner
p. 16
“we mentioned the 15% EBITDA margins, that's the minimum target that we're going to focus.”
Alexander Poempner, page 16 of the filed PDF · View the filing
Tax rate — around 30%, maybe slightly below · 18 to 24 months
stated conditionally by Alexander Poempner
p. 25
“regarding the timing of the tax rate, to bring it down, we indicated 18 to 24 months. And the debt, the refinancing and the reorganization has to be completed first.”
Alexander Poempner, page 25 of the filed PDF · View the filing
Debt restructuring — 12 to 18 months
stated conditionally by Alexander Poempner
p. 25
“And then we will restructure our debt position and further reduce it. And this will take, as mentioned, the time frame 12 to 18 months.”
Alexander Poempner, page 25 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said pharma demand in India and internationally is improving while chemicals remains flat/challenged.
Answered by Tarak Patel
Asked by Sameer Thakur: Are there signs of recovery in chemical and pharma end markets and has competitive intensity eased?
p. 11
“we are seeing a lot of action in pharma in Hyderabad, CDMO so that's driving a lot of investments and that's helping us build backlog in our local Indian glass-lined business.”
Tarak Patel, page 11 of the filed PDF · View the filing
Management attributed the decline to a higher mix of HET business and new investments, expecting improvement over time.
Answered by Ankit Nayyar
Asked by Sameer Thakur: Why did Indian standalone margins decline and how should this trend going forward?
p. 13
“we are also investing in costs. As you would have heard, we have invested into the new organization, so we are investing in people and that's why you see a dip in margins, but these are good investments happening for the future, so you will see an upward trend going forward.”
Ankit Nayyar, page 13 of the filed PDF · View the filing
Management said divisions are broadly around the 15% aspirational margin range without differentiating sharply between them.
Answered by Tarak Patel
Asked by Praveen Kumar: What is the margin profile and ROCE across the four new divisions and which are closer to steady-state margins?
p. 16
“currently the businesses and the verticals that now we have created, somewhat kind of have along that kind of margin profile.”
Tarak Patel, page 16 of the filed PDF · View the filing
Management declined to give a specific cadence, saying they are moving in the right direction with multiple initiatives underway.
Answered by Tarak Patel
Asked by Praveen Kumar: What is the cadence and timeframe for reaching 15%+ margins?
p. 17
“we are going the right direction, and let’s focus on them, let's maybe build some kind of momentum with order intake in Q2 and when we meet again next quarter maybe hopefully, we'll have a much clearer picture in terms of where we are going to end up and what the future holds.”
Tarak Patel, page 17 of the filed PDF · View the filing
Management reiterated debt repayment of EUR 7 million this quarter but declined to give specific year-end debt or margin targets.
Answered by Alexander Poempner
Asked by Sagar Shah: What target EBITDA margins and debt levels are being aimed for over FY27-FY28?
p. 21
“We will repay approximately EUR 7 million this quarter and we are working on the refinancing alternative that will bring further down our debt and we dont to comment on the debt as of the end of this financial year, but as you see we are working on this and we will further reduce over the coming quarters”
Alexander Poempner, page 21 of the filed PDF · View the filing
Management described broad-based order growth across India, US, China and Europe in CRT, driven by pharma and peptide investment, while noting uncertainty on sustainability.
Answered by Tarak Patel
Asked by Dhavan Shah: Is the order inflow growth for CRT and PPT structural or one-time, and what is the outlook for coming quarters?
p. 22
“CRT is looking good globally, Europe still looks a bit tough but the other geographies are looking a lot more positive.”
Tarak Patel, page 22 of the filed PDF · View the filing
Management said a large majority of the roughly INR 1000 crore order intake is executable within that window, unlike last year's multi-year project mix.
Answered by Gregory Gelhaus
Asked by Rushabh: What percentage of the order book is executable within 10 to 12 months?
p. 26
“significant amount of the - roughly 1000 crores order intake that we had, significant amount of that is executable in the next 10 to 12 months.”
Gregory Gelhaus, page 26 of the filed PDF · View the filing
Management declined to give a specific debt figure, citing the need to first restructure the group's legal entities.
Answered by Alexander Poempner
Asked by Rushabh: Can management specify a debt reduction target and timeline?
p. 25
“I will not mention our debt target figure for end of this year.”
Alexander Poempner, page 25 of the filed PDF · View the filing
Management confirmed no one-off severance cost and said employee costs would be optimized over time through low-cost geography shifts.
Answered by Tarak Patel
Asked by Ravi Mehta: Was there any one-off severance cost in Q1 and will employee cost investment continue rising?
p. 26
“the idea is to bring down employee costs over time.”
Tarak Patel, page 26 of the filed PDF · View the filing
Management guided to an interest cost range and explained the current order book has a shorter execution cycle than the prior year.
Answered by Alexander Poempner
Asked by Simran Kumari: What interest cost should be modeled for FY27/FY28 and what is the order intake trajectory expected?
p. 27
“The interest cost we have on average 6% to 7%.”
Alexander Poempner, page 27 of the filed PDF · View the filing
Risks flagged
Continued pricing pressure and revolving business mix pressuring EBITDA
p. 8
“EBITDA was lower by 7%, primarily reflecting continued pricing pressure in a revolving business mix and investments towards strengthening our global organization structure.”
Alexander Poempner, page 8 of the filed PDF · View the filing
Chemicals demand remaining flat/challenged in India and Europe
p. 12
“Chemicals unfortunately in India has still remained flat.”
Tarak Patel, page 12 of the filed PDF · View the filing
Chemical sector challenges persisting in Europe
p. 12
“it remains very challenging from the chemical sector.”
Gregory Gelhaus, page 12 of the filed PDF · View the filing
Underperforming units dragging down group margins
p. 17
“What we're currently suffering on is that we have one, two, three units which are really underperforming, and which are dragging the margin down.”
Alexander Poempner, page 17 of the filed PDF · View the filing
Complex international legal entity structure adding financing and tax costs
p. 10
“this structure provided global reach, it also resulted in additional financing costs, overlapping administrative structures, into more complex tax and corporate framework.”
Alexander Poempner, page 10 of the filed PDF · View the filing
Order inflow growth this quarter could be one-off rather than sustainable
p. 24
“Again, like you said also sometimes it could be a one-off, two-off quarter kind of an investment. We hope it's sustainable.”
Tarak Patel, page 24 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.